Cargando…

Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia

The role of cefepime for extended-spectrum β-lactamase (ESBL) bacteremia is unclear if susceptible in vitro. In a propensity score-matched study of patients with ESBL bacteremia, risk of death was 2.87 times higher for patients receiving cefepime compared with carbapenems (95% confidence interval [C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ruibin, Cosgrove, Sara E., Tschudin-Sutter, Sarah, Han, Jennifer H., Turnbull, Alison E., Hsu, Alice J., Avdic, Edina, Carroll, Karen C., Tamma, Pranita D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942761/ https://www.ncbi.nlm.nih.gov/pubmed/27419191 http://dx.doi.org/10.1093/ofid/ofw132

Ejemplares similares

Reporting Extended-Spectrum β-Lactamase Positivity May Reduce Carbapenem Overuse
por: Tamma, Pranita D, et al.
Publicado: (2019)

Clinical Outcomes of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Infections with Susceptibilities among Levofloxacin, Cefepime, and Carbapenems
por: Walker, Kristy J., et al.
Publicado: (2018)

In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae
por: Crandon, Jared L., et al.
Publicado: (2015)

Clinical Impact of Revised Cefepime Breakpoint in Patients With Enterobacteriaceae Bacteremia
por: Foong, Kap Sum, et al.
Publicado: (2019)

716 Risk Factors for Resistance to Beta-lactam/Beta-lactamase Inhibitors and Carbapenems in Bacteroides spp. Bacteremia
por: Smith, Janessa, et al.
Publicado: (2014)

Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study
por: Su, Ting-Yi, et al.
Publicado: (2017)

160. Antimicrobial Prescribing Patterns in Bloodstream Infections Caused by Cefepime-Susceptible Extended Spectrum β-lactamase Enterobacterales
por: O’Rourke, Emerald, et al.
Publicado: (2022)

Cefepime MIC as a Predictor of the Extended-Spectrum β-Lactamase Type in Klebsiella pneumoniae, Taiwan
por: Yu, Wen Leong, et al.
Publicado: (2002)

Cefepime: Cefepime-induced encephalopathy: case report
Publicado: (2022)

Risk factors for colonization with multiple species of extended-spectrum beta-lactamase producing Enterobacterales: a case-case–control study
por: Vock, Isabelle, et al.
Publicado: (2021)

1588. Clinical Prediction Tool for Extended-Spectrum Β Lactamase-Producing Enterobacteriaceae as the Etiology of Bacteremia in Solid Organ Transplant Recipients
por: Wang, Rebecca, et al.
Publicado: (2018)

Independent, external validation of clinical prediction rules for the identification of extended-spectrum β-lactamase-producing Enterobacterales, University Hospital Basel, Switzerland, January 2010 to December 2016
por: Vock, Isabelle, et al.
Publicado: (2020)

52. Development and Implementation of a Short Duration of Antibiotic Therapy Algorithm for Uncomplicated Gram-Negative Bacteremia
por: Bae, Esther Y, et al.
Publicado: (2020)

In vitro and in vivo efficacy study of cefepime, doripenem, tigecycline, and tetracycline against extended-spectrum beta-lactamases Escherichia coli in chickens
por: Tarazi, Yaser Hamadeh, et al.
Publicado: (2020)

Cefepime-induced encephalopathy
por: Kenzaka, Tsuneaki, et al.
Publicado: (2018)

Cefepime-Induced Encephalopathy
por: Keerty, Dinesh, et al.
Publicado: (2021)

Cefepime-Induced Neurotoxicity
por: Saini, Tanjot, et al.
Publicado: (2021)

Cefepime-Induced Delirium
por: Somoza-Cano, Francisco J, et al.
Publicado: (2021)

In Vitro Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing Enterobacterales Collected in India
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2023)

Predictors of mortality from extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia
por: Namikawa, Hiroki, et al.
Publicado: (2023)

Activity of the Novel Extended-spectrum β-Lactamase Inhibitor AAI101 in Combination with Cefepime Towards a Challenge Panel of Acinetobacter baumannii
por: Morrissey, Ian, et al.
Publicado: (2017)

1228. Outcomes Associated with Empiric Cefepime or Meropenem for Bloodstream Infections Caused by Ceftriaxone-Resistant, Cefepime-Susceptible Escherichia coli and Klebsiella pneumoniae
por: Frescas, Brian E, et al.
Publicado: (2021)

Cefepime-Resistant Pseudomonas aeruginosa
por: Akhabue, Ehimare, et al.
Publicado: (2011)

Some Pharmacodynamic Aspects of Cefepime
por: Elsayed, Mossad Gamaleddin Ahmed, et al.
Publicado: (2013)

Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI)
por: Vu, Catherine H., et al.
Publicado: (2022)

1318. Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment
por: Geibel, Brooke, et al.
Publicado: (2020)

In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model
por: Abdelraouf, Kamilia, et al.
Publicado: (2023)

Cefepime extended infusion versus intermittent infusion: Clinical and cost evaluation
por: Khole, Aalok V., et al.
Publicado: (2023)

Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli
por: Seo, Yu Bin, et al.
Publicado: (2017)

Cefepime Neurotoxicity in Patients with Renal Insufficiency
por: Kim, Seon-Yu, et al.
Publicado: (2012)

Stevens-Johnson syndrome caused by cefepime?
por: Luciano, Mavilia, et al.
Publicado: (2015)

High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2023)

133. ARGONAUT-III: Susceptibility of Carbapenem-resistant Klebsiellae to Cefepime-Taniborbactam
por: Mack, Andrew R, et al.
Publicado: (2021)

Cefepime-induced neurotoxicity: a systematic review
por: Payne, Lauren E., et al.
Publicado: (2017)

P081: Cefepime-tazobactam: a new antibiotic against ESBL producing enterobacteriaceae in cancer patients
por: Biswas, S, et al.
Publicado: (2013)

The Frequency of Extended-Spectrum β-Lactamase Genes Harbored by Enterobacterales Isolates at High Risk for Clinically Significant Chromosomal ampC Expression
por: Hareza, Dariusz, et al.
Publicado: (2023)

Comparing the Outcomes of Adults with Enterobacteriaceae Bacteremia Receiving Short-Course vs Prolonged-Course Antibiotic Therapy
por: Chotiprasitsakul, Darunee, et al.
Publicado: (2017)

1055. Epidemiology and Mechanisms of Carbapenem Resistance in Recurrent Extended-Spectrum β-Lactamase- Producing Enterobacteriaceae Bacteremia
por: Aitken, Samuel L, et al.
Publicado: (2018)

211. Disease burden of bacteremia with extended-spectrum beta-lactamase-producing or carbapenem-resistant Enterobacteriaceae in Korea
por: Mi Lee, Chan, et al.
Publicado: (2023)

VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
por: Hamrick, Jodie C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tm3h0ka3oopp331oqoagg278lk